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Received 27 February 2008; received in revised form 13 May 2008; accepted 15 May 2008; Available online 6 August 2008AbstractObjective:Management of the left atrial appendage (LAA) is considered an important adjunct to ablation in cardiac surgical patients with atrial
fibrillation (AF). However, current surgical techniques, both cut-and-sew and stapling, have been associated with incomplete LAA occlusion and
complications. Using cardiac magnetic resonance imaging (MRI), we studied the safety and effectiveness of a new device for LAA occlusion in a
primate model. Methods: Seven adult baboons underwent off-pump placement of an LAA clip (AtriCure Inc., Westchester, Ohio). LAA occlusion
was confirmed intraoperatively by direct incision. All animals had MRI before and after clip placement to assess LAA perfusion, architecture, and
overall cardiac function. Pathologic and histological studies were performed at 7, 30 and 180 days. Results: Clip placement was successful in all
(n = 7) without any clip related complications. Complete LAA occlusion was demonstrated intraoperatively in all subjects. LAA occlusion was
confirmed on pre-sacrifice MRI, and left and right ventricular function were unchanged from preoperative studies; however, clip placement
caused small reductions in left ventricular end-diastolic, end-systolic, and stroke volumes. At sacrifice, direct inspection confirmed stable
location, persistent LAA exclusion, tissue in-growth and homogenous epithelialization without damage to adjacent structures. Histological
analysis revealed a regular in-growth pattern in all studied specimens. Conclusion: We demonstrated a safe, straightforward, persistent and
effective method for LAA occlusion with this new LAA clip. MRI effectively demonstrated LAA occlusion and only minor changes in left ventricular
volumes.
# 2008 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
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Patients with atrial fibrillation (AF) have a five-fold
increased risk of stroke, and it is hypothesized that most
embolic strokes in such patients arise from thrombi forming
in the left atrial appendage (LAA) [1]. In patients undergoing
cardiac surgery for AF, the current guidelines recommend
some form of LAA amputation for patients undergoing mitral
valve surgery [2]. In an attempt to provide minimally invasive
solutions for LAA management, novel percutaneous
approaches have been developed which come with the risks
of LAA injury, incomplete occlusion, and device dislocation
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doi:10.1016/j.ejcts.2008.05.058can be accessed from the pericardial space, it is likely that a
properly constructed device placed from the epicardial
surface of the LAA will be both safe and effective. Currently,
there is considerable interest in the development of new
technologies for management of the LAA. This study used
magnetic resonance imaging (MRI) to assess the impact of LAA
exclusion with a new epicardial clip in a healthy primate
model.2. Materials and methods
This study utilized eight adult primate animals (Papio
anubis), and was composed of two substudies. The first trial
was a pulmonary vein isolation with a new bipolar ablation
device (manuscript in preparation) and the second actual LAA
clip deployment. Throughout the trial animal welfare was
closely supervised by a trained veterinarian team. Prior to
the start of the study, time points for study termination were
defined at 7, 30 and 180 days. The animals were randomly
assigned to the different time points. All the animalsurgery. Published by Elsevier B.V. All rights reserved.
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Fig. 1. Clip on standard open chest deployment tool.
Fig. 2. Intraoperative view after clip (25 mm) deployment on 17 kg female
baboon.underwent MRI both before clip placement and before
sacrifice (Fig. 4a). The procedures were all performed
aseptically in an American Association for Laboratory Animal
Science (AALAS) approved facility. The protocol was
approved by the Institutional Animal Care and Use Commit-
tee (IACUC) at Mount Sinai School of Medicine, and all
experimental procedures were consistent with the Guide for
the Care and Use of Laboratory Animals.
This second generation LAA clip was developed by
AtriCure Inc. (West Chester, Ohio, USA). The first generation
clip [6] had a curved design with the identical components
and performance as the current straight version; however the
titanium parallel elements had a 2 in radius of curvature. The
curvature was originally intended to aid in accessing the
anatomy of the LAA. However, it was determined in animal
testing that the curvature of the parallel titanium (tubes)
elements did not aid in accessibility and was therefore
unnecessary. The current design is virtually identical to the
initial device, with the exception of having straight parallel
members instead of slightly curved parallel members (Fig. 1).
All materials in the device are the same for both versions of
the clip and are composed of a deflectable nitinol frame
covered with a proprietary polyester mesh. The internal
design of the clip consists of two polycarbonate elastomers,
two nitinol springs, and two titanium elements. The nitinol
springs provide the clamping force needed to approximate
the LAA tissue thus providing immediate occlusion. The
polyester mesh assists in the pressure distribution as well as
serving as a matrix for epithelial tissue growth. The clip
comes in different sizes, based on the length of the LAA base
(from 25 mm to 45 mm in 10 mm steps). In this study a 25 mm
clip was used in all animals. The applier is configured such
that the clip can be removed and redeployed if initial
deployment is judged to be unsatisfactory.
MRI was performed in a 1.5-T clinical magnet (Magneton
Sonata#, Siemens Medical Solutions, Erlangen, Germany)
with a dedicated cardiac coil. Maximum and minimum end-
systolic, end-diastolic and stroke volumes were quantified as
previously described [7]. In addition, the long-axis views
were employed to determine flow in the left atrial
appendage.3. Surgical implant
After endotracheal anesthesia, median sternotomy and
pericardial incision were performed. In addition to LAA
exclusion with the LAA clip, a complete off-pump epicardial
modified Cox Maze IV lesion set was performed with a bipolar
pen and clamp. While manually stabilizing the heart, the clip
was lowered onto the LAA and deployed at its base. Care was
taken to orient the clip parallel to the base of the appendage
and not to impinge upon the circumflex coronary or
pulmonary artery. Confirmation of circulatory exclusion
and non-perfusion of the LAA was assessed by incising the
LAA distal to the clip. The defect was then oversewn with a
7/0 Prolene suture.
On the day of the terminal study an MRI was performed to
assess cardiac function, patency of the pulmonary veins, and
circulatory exclusion of the LAA. After the MRI, the chest was
re-entered through the original incision to expose the heart
with the clip, after which full heparinization proceeded
humane euthanasia and en-bloc cardiac resection.4. Results
4.1. Surgical results
Clip placement was swift and straightforward. The clip
was successfully deployed in a satisfactory manner on the
first attempt (Fig. 2). No conflict with any surrounding
structures (coronary artery, pulmonary artery, or left atrial
body) was noted. Postdeployment, direct intraoperative LAA
incision demonstrated total circulatory isolation from the
left atrium, with absence of blood within the LAA (Fig. 3).
Additionally, we performed a complete left atrial epicardial
ablation using a bipolar ablation/pacing pen (AtriCure Inc.,
Westchester, OH). All of the animals survived the procedure
and there were no intra- or postoperative complications due
to clip placement or ablation.
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Fig. 3. Intraoperative view after incision of LAA. No LAA perfusion confirmed
on the beating heart.
Fig. 4. (a) MRI depicting LAA before clip placement (white circle). (b) MRI 180
days after clip placement showing shadow of clip and no LAA (white circle).One death occurred on postoperative day 1 due to acute
respiratory failure in an older female subject. The other
animals survived in excellent health until their randomly pre-
assigned time points of 7 days (n = 2), 30 days (n = 2) and 180
days (n = 2). No animal appeared sick or required medical
attention during the entire study period. At sacrifice, all
animals were in documented sinus rhythm.
Preoperative MRI demonstrated normal cardiac architec-
ture and function in all animals (mean EF 54%) (Table 1). The
LAAwas readily identified on MRI in all animals. There was an
interspecies variation of ejection fraction and cardiac
volumes, as these were wild animals of different age, gender
and physical constitution. On pre-sacrifice MRI, left ven-
tricular function was seen to be preserved (mean EF 52%).
The LAA was present at 7 days, totally retracted at 30 days
and macroscopically unidentifiable with only a slight shadow
on the MRI pointing to the presence of the clip at 6 months
(n = 2) (Fig. 4b). MRI also demonstrated normal adjacent
tissues without erosion or spatial displacement. Quantitative
calculation from cardiac MRI images revealed a discrete
decrease in stroke volumes, end-diastolic volumes and
systolic volumes when compared to preoperative values
(Table 1). The clip components did not cause any artifact to
the MRI imaging. The MRI provided impeccable sliced for
quantitative analysis and functional imagery for real time
reproduction of cardiac function.Table 1
Quantitative MRI data
Animals EF1 EF2 Diff ED1 ED2 Dif
7 d_1 53 42 11 38 30 
7 d_2 46 45 1 22 19 
30 d_1 62 60 2 27 16 1
30 d_2 53 50 3 24 21 
180 d_1 56 56 1 33 20 1
180 d_2 57 56 1 21 21
Pre, before clip; post, after clip; EF, ejection fraction; ED, end-diastolic volume; E4.2. Pathology
At gross epicardial inspection, the LAA clip was easily
identified in all animals. At 7 days the LAA was present but
empty and there were no pericardial adhesions. At 30 days
the LAAwas still identifiable, but there were adhesions at the
epicardial aspect. By 180 days, the LAAwas no longer presentf ES1 ES2 Diff SV1 SV2 Diff
8 18 18 0 20 13 7
3 12 11 1 10 9 1
1 11 6 5 10 8 2
3 11 9 2 13 13 0
3 14 9 5 19 11 8
0 9 9 0 12 12 0
S, end-systolic volume; SV, stroke volume.
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Fig. 5. Intraoperative photograph showing atrial surface of LAA occluded by
the LAA clip. A smooth surface of endothelium covers the remaining few
millimeter long ‘cul-de-sac’.and the clip was completely covered by tissue in-growth.
There was no erosion into adjacent structures (e.g. the
circumflex coronary artery, pulmonary artery, or left atrium).
Examination of the endocardial surface of the left atrium
revealed no thrombus in any animal. At 6 months, the LAA
opening appeared to be covered by a smooth endocardial
tissue layer (Fig. 5).
4.3. Histology
On microscopic examination, a regular growth pattern
was seen on the polyester grain covering the clip. At 7 days,
the cross sections through the clip showed healing mural
necrosis. After 30 and 180 days main findings included a fibrous
replacement scar between the two clip arms in addition to a
smooth layer of endothelial cells on the atrial side.5. Discussion
In this first primate trial, we have demonstrated safe,
straightforward, dependable and effective LAA occlusion
with a novel epicardial LAA clip. Moreover, with the use of
cardiac MRI we have clearly shown that LAA occlusion is
durable and that LAA exclusion with the LAA clip device does
not substantially impact cardiac function.
During cardiac surgery, the most common technique for
LAA occlusion is to perform suture ligation from within or
epicardially, concomitant to a maze or left atrial ablative
procedure. While LAA management is a common component
of surgical ablation as an adjunct to heart valve surgery,
there is limited data documenting safety and clinical impact
of stand-alone LAA ligation or excision. In a recent series [9]
with 15 patients and 3 year follow-up, thoracoscopic stand-
alone LAA ligation was shown to be feasible and potentially
beneficial; however, in one patient intraoperative LAA injury
occurred, requiring emergency thoraocotomy. This report
highlights the interest but also emphasizes the challenge and
difficulty in surgically addressing the LAA [9].There has been recent interest in assessment of surgical
techniques for LAA management during open-heart surgery.
In a recent report from the left Atrial Appendage Occlusion
Study (LAAOS) where patients without AF were randomized
to LAA occlusion during routine coronary artery bypass
grafting [10], the authors found that LAA occlusion is safe.
However, they found that suture ligation was frequently
incomplete, allowing continued blood flow into the LAA. In
addition, stapled excision often left a large cul-de-sac,
amounting to an incomplete left atrial appendage excision
[10]. Thus, advances in technique and technology are
necessary.
The new LAA clip presented herein, addresses another
limitation of LAA occlusion, which is the wide spectrum of
LAA dimensions present in patients with AF. The hetero-
geneity of LAA dimensions in patients with AF has recently
been documented in an MRI series [12]. It is well established
that complete and effective LAA occlusion are paramount to
ensure optimal clinical outcomes [13]. The availability of the
clip in several different sizes, accommodating the variety of
LAA bases, will most certainly be beneficial in this patient
population and help ensure complete LAA occlusion.6. Summary
In this series, we have shown the LAA clip to enable
effective and durable epicardial LAA occlusion in healthy
primates. It is straightforward to implant and there were no
device related complications. MRI demonstrates only minor
impact on cardiac volumes without important changes in
cardiac function. These animals were in sinus rhythm and
had normal cardiac function; therefore, it is possible that
clinical results in humans with AF and structural heart
disease will differ from the findings in this study. However,
human clinical trials in patients with AF undergoing open-
heart surgery are currently underway. In addition, a
thoracoscopic platform for clip application and AF ablation
is under development.
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